12:00 AM
 | 
Mar 19, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Rating Wk chg 3/16 cls
Adventrx (ANX) ThinkEquity Vinny Jindal New Buy -5% $1.98
Jindal set a $5 target. He sees the company's CoFactor (ANX-510) as a potential target for partnering, and expects results from a Phase IIb trial comparing the compound to leucovorin in metastatic colorectal cancer in 2H07. The folate-based active metabolite of leucovorin is also in Phase III testing for metastatic colorectal cancer and in Phase II for advanced breast cancer.
Amarin (AMRN; LSE:AMRN) Davy Securities Jack Gorman Price target NA 18% $2.57
Gorman raised his target to $8.50 from $3.10, citing higher potential pricing of Miraxion (LAX-101) in Huntington's disease. He thinks a successful launch in mid-2008 would turn AMRN profitable next year.
Amgen (AMGN) Baird Christopher Raymond Price target Market outperform -3%...

Read the full 818 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >